News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Trius Therapeutics (TSRX) Reports Data on Broad-Spectrum Antibiotics at 52nd Annual ICAAC Meeting


9/13/2012 9:41:10 AM

SAN FRANCISCO, Sept. 12, 2012 (GLOBE NEWSWIRE) -- ICAAC 2012 -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections, today announced preclinical studies related to a new class of broad-spectrum, gram-negative antibacterial agents that are directed against novel targets Gyrase B (GyrB) and ParE. Trius scientists and research collaborators are presenting the results at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting being held in San Francisco from September 9-12, 2012. Fourteen posters and one podium presentation related to the company's GyrB/ParE preclinical program are being featured, including both in vivo and in vitro studies.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES